Updating results

455 results

Sort: Relevance | Date

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 26 August 2020

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 23 February 2020

Technology appraisal guidance In development

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

In development [GID-TA10468] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468

In development [GID-TA10351] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Mogamulizumab for treated mycosis fungoides or Sézary syndrome T-cell lymphoma ID1405

In development [GID-TA10305] Expected publication date: 16 September 2020

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated squamous non-small-cell lung cancer ID1559

In development [GID-TA10516] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Lenalidomide for previously treated follicular lymphoma and marginal zone lymphoma

In development [GID-TA10323] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

In development [GID-TA10186] Expected publication date: 08 January 2020

Technology appraisal guidance In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Ivosidenib for treating relapsed or refractory acute myeloid leukaemia ID1548

In development [GID-TA10416] Expected publication date: 02 December 2020

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Solriamfetol for treating excessive sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404

In development [GID-TA10327] Expected publication date: TBC

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Patiromer for treating hyperkalaemia [ID877]

In development [GID-TA10273] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421]

In development [GID-TA10379] Expected publication date: 20 November 2019

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [ID981]

In development [GID-TA10107] Expected publication date: 20 November 2019

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Entrectinib for treating NTRK fusion-positive solid tumours ID1512

In development [GID-TA10414] Expected publication date: 12 February 2020

Technology appraisal guidance In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome [ID1211]

In development [GID-TA10274] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome [ID1308]

In development [GID-TA10410] Expected publication date: 18 December 2019

Technology appraisal guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development